citalopram has been researched along with Chemical Dependence in 26 studies
Citalopram: A furancarbonitrile that is one of the serotonin uptake inhibitors used as an antidepressant. The drug is also effective in reducing ethanol uptake in alcoholics and is used in depressed patients who also suffer from TARDIVE DYSKINESIA in preference to tricyclic antidepressants, which aggravate dyskinesia.
citalopram : A racemate comprising equimolar amounts of (R)-citalopram and its enantiomer, escitalopram. It is used as an antidepressant, although only escitalopram is active.
1-[3-(dimethylamino)propyl]-1-(4-fluorophenyl)-1,3-dihydro-2-benzofuran-5-carbonitrile : A nitrile that is 1,3-dihydro-2-benzofuran-5-carbonitrile in which one of the hydrogens at position 1 is replaced by a p-fluorophenyl group, while the other is replaced by a 3-(dimethylamino)propyl group.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Outpatients with nonpsychotic major depressive disorder treated for up to 14 weeks with citalopram in the first step of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study were divided by household incomes of <$20,000, $20,000-<$40,000, and >or=$40,000." | 5.14 | Income and attrition in the treatment of depression: a STAR*D report. ( Balasubramani, GK; Lesser, IM; Nierenberg, AA; Rush, AJ; Shores-Wilson, K; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR, 2009) |
| "Bupropion's efficacy for smoking cessation in pregnant women is unknown." | 5.14 | The relationship between antidepressant use and smoking cessation in pregnant women in treatment for substance abuse. ( Brigham, EP; Chisolm, MS; Jones, HE; Strain, EC; Tuten, M, 2010) |
| "The purpose of the present study is to determine the role of lidocaine, caffeine and dextromethorphan, used as adulterant substances, in five cases of drug overdose which have come to our attention." | 3.79 | The pathogenetic role of adulterants in 5 cases of drug addicts with a fatal outcome. ( Barbera, N; Busardò, FP; Indorato, F; Romano, G, 2013) |
| "Most patients with major depressive disorder (MDD) report clinically significant sleep problems." | 2.80 | Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report. ( Luther, JF; Rush, AJ; Sung, SC; Trivedi, MH; Wisniewski, SR, 2015) |
| "The co-occurrence of substance use disorder (SUD) and major depressive disorder (MDD) is common and is often thought to impair response to antidepressant therapy." | 2.77 | Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial. ( Balasubramani, GK; Davis, LL; Fava, M; Gaynes, BN; Howland, RH; Pilkinton, P; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2012) |
| "Many patients with major depressive disorder (MDD) present with concurrent substance use disorders (SUDs), which has been thought to impair their response to antidepressants." | 2.75 | Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes. ( Balasubramani, GK; Davis, LL; Fava, M; Howland, RH; Husain, MM; McGrath, PJ; Rush, AJ; Trivedi, MH; Warden, D; Wisniewski, SR, 2010) |
| "Untreated major depressive disorder (MDD) is a major risk factor for suicide, but some data suggest antidepressants may be associated with increased suicidal ideation (SI) in some depressed patients." | 2.74 | Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study. ( Fava, M; Lebowitz, B; Luther, J; Moutier, C; Rush, AJ; Stewart, JW; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR; Zisook, S, 2009) |
| "Citalopram was delivered using measurement-based care and flexible dosing with the aim of achieving symptom remission." | 2.74 | Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial. ( Balasubramani, GK; Fava, M; Friedman, ES; Gilmer, W; Nierenberg, AA; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2009) |
| "Those with concurrent drug abuse and recurrent major depressive disorder were less likely to accept a switch strategy." | 2.73 | Acceptability of second-step treatments to depressed outpatients: a STAR*D report. ( Biggs, MM; Fava, M; Friedman, ES; Lavori, PW; McGrath, PJ; Miyahara, S; Niederehe, G; Rush, AJ; Sackeim, HA; Shores-Wilson, K; Thase, ME; Trivedi, MH; Warden, D; Wisniewski, SR, 2007) |
| "Three cases of patients presenting a substance use disorder with comorbid major depression episodes are presented, who were treated with a reboxetine/escitalopram combination and who showed a rapid response of their depressive syndrome." | 2.71 | Escitalopram/reboxetine combination in depressed patients with substance use disorder. ( Camarasa, X; Duboc, A; Khazaal, Y; Lopez-Martinez, E; Zullino, DF, 2005) |
| " Moreover, chronic administration of psychostimulants can cause enduring changes in neurobiology reflected in dysregulation of monoamine neurochemistry and behavior." | 2.50 | Monoamine transporter inhibitors and substrates as treatments for stimulant abuse. ( Howell, LL; Negus, SS, 2014) |
| "No cardiac rhythm disturbances or convulsions were seen." | 1.56 | Citalopram intoxication in four week old infant. ( Eijkemans, M; Janson, JA; Kerskes, M; Wasylewicz, ATM, 2020) |
| "Mitragynine is a novel psychoactive substance (NPS) that has emerged as a designer opioid being distributed on the street." | 1.48 | Suspected Driving Under the Influence Case Involving Mitragynine. ( Wright, TH, 2018) |
| "Depressive disorders are involved as a background factor in over 50% of suicide cases." | 1.46 | Serotonergic 5HTTLPR/rs25531 s-allele homozygosity associates with violent suicides in male citalopram users. ( Haukka, J; Majaharju, S; Palo, JU; Rahikainen, AL; Sajantila, A, 2017) |
| "Participants with either anxiety or substance use disorder showed outcomes generally intermediate between those with both and those with neither." | 1.35 | Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome. ( Balasubramani, GK; Berman, SR; Davis, LL; Fava, M; Howland, RH; McGrath, PJ; Rush, AJ; Trivedi, MH; Warden, D; Wisniewski, SR, 2009) |
| "Thirty youth with major depressive disorder (MDD) and 23 control youth reported on caffeine use, sleep, and affect in their natural environment using ecological momentary assessment at baseline and over 8 weeks, while MDD youth received treatment." | 1.35 | Caffeine consumption, sleep, and affect in the natural environments of depressed youth and healthy controls. ( Axelson, DA; Birmaher, B; Dahl, RE; Forbes, EE; Ryan, ND; Semel, M; Silk, JS; Whalen, DJ, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (3.85) | 18.2507 |
| 2000's | 12 (46.15) | 29.6817 |
| 2010's | 11 (42.31) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Hung, CC | 1 |
| Lee, CH | 1 |
| Ko, AM | 1 |
| Lane, HY | 1 |
| Lee, CP | 1 |
| Ko, YC | 1 |
| Janson, JA | 1 |
| Wasylewicz, ATM | 1 |
| Eijkemans, M | 1 |
| Kerskes, M | 1 |
| Rahikainen, AL | 1 |
| Majaharju, S | 1 |
| Haukka, J | 1 |
| Palo, JU | 1 |
| Sajantila, A | 1 |
| Wright, TH | 1 |
| Spada, MM | 1 |
| Howell, LL | 1 |
| Negus, SS | 1 |
| Papp, M | 1 |
| Gruca, P | 1 |
| Lason-Tyburkiewicz, M | 1 |
| Litwa, E | 1 |
| Willner, P | 1 |
| Sung, SC | 1 |
| Wisniewski, SR | 11 |
| Luther, JF | 1 |
| Trivedi, MH | 11 |
| Rush, AJ | 11 |
| Vincenzi, FF | 1 |
| Howland, RH | 3 |
| Warden, D | 6 |
| Fava, M | 7 |
| Davis, LL | 3 |
| Balasubramani, GK | 7 |
| McGrath, PJ | 3 |
| Berman, SR | 1 |
| Husain, MM | 2 |
| McClintock, SM | 1 |
| Nierenberg, AA | 4 |
| Davis, L | 1 |
| Young, E | 1 |
| Albala, AA | 1 |
| Zisook, S | 3 |
| Lebowitz, B | 1 |
| Thase, ME | 3 |
| Stewart, JW | 1 |
| Moutier, C | 1 |
| Luther, J | 1 |
| Friedman, ES | 3 |
| Gilmer, W | 1 |
| Lesser, IM | 1 |
| Shores-Wilson, K | 2 |
| Masand, P | 1 |
| Narasimhan, M | 1 |
| Shelton, RC | 1 |
| Hollon, SD | 1 |
| Alpert, JE | 2 |
| Preskorn, SH | 1 |
| Chisolm, MS | 1 |
| Brigham, EP | 1 |
| Tuten, M | 1 |
| Strain, EC | 1 |
| Jones, HE | 1 |
| Pilkinton, P | 1 |
| Gaynes, BN | 2 |
| Barbera, N | 1 |
| Busardò, FP | 1 |
| Indorato, F | 1 |
| Romano, G | 1 |
| Camarasa, X | 1 |
| Lopez-Martinez, E | 1 |
| Duboc, A | 1 |
| Khazaal, Y | 1 |
| Zullino, DF | 1 |
| Vari, G | 1 |
| Beckson, M | 1 |
| Niederehe, G | 1 |
| Biggs, MM | 2 |
| Sackeim, HA | 1 |
| Lavori, PW | 1 |
| Miyahara, S | 1 |
| Whalen, DJ | 1 |
| Silk, JS | 1 |
| Semel, M | 1 |
| Forbes, EE | 1 |
| Ryan, ND | 1 |
| Axelson, DA | 1 |
| Birmaher, B | 1 |
| Dahl, RE | 1 |
| Barkin, JL | 1 |
| Stein, DJ | 1 |
| Rink, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| Motivational Interviewing to Reduce Substance Use Among Depression Patients[NCT02420561] | 307 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for citalopram and Chemical Dependence
| Article | Year |
|---|---|
An overview of problematic internet use.
Topics: Antidepressive Agents, Second-Generation; Behavior, Addictive; Central Nervous System Stimulants; Ci | 2014 |
Monoamine transporter inhibitors and substrates as treatments for stimulant abuse.
Topics: Animals; Central Nervous System Stimulants; Citalopram; Cocaine-Related Disorders; Dose-Response Rel | 2014 |
11 trials available for citalopram and Chemical Dependence
| Article | Year |
|---|---|
Effect of antidepressants for cessation therapy in betel-quid use disorder: a randomised, double-blind, placebo-controlled trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Areca; Asian People; Citalopram; Double-Blind Method | 2020 |
Pre-treatment insomnia as a predictor of single and combination antidepressant outcomes: a CO-MED report.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Citalopram; Comorbidit | 2015 |
Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D study.
Topics: Adult; Citalopram; Depressive Disorder, Major; Diagnostic and Statistical Manual of Mental Disorders | 2009 |
Sociodemographic, clinical, and treatment characteristics associated with worsened depression during treatment with citalopram: results of the NIMH STAR(*)D trial.
Topics: Adolescent; Adult; Aged; Black or African American; Citalopram; Demography; Depressive Disorder, Maj | 2009 |
Income and attrition in the treatment of depression: a STAR*D report.
Topics: Adolescent; Adult; Age Factors; Aged; Ambulatory Care; Citalopram; Cognition Disorders; Depressive D | 2009 |
Does comorbid substance use disorder impair recovery from major depression with SSRI treatment? An analysis of the STAR*D level one treatment outcomes.
Topics: Adolescent; Adult; Aged; Alcohol-Related Disorders; Chi-Square Distribution; Citalopram; Comorbidity | 2010 |
The relationship between antidepressant use and smoking cessation in pregnant women in treatment for substance abuse.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depressive Disorder, Major; | 2010 |
Effect of concurrent substance use disorder on the effectiveness of single and combination antidepressant medications for the treatment of major depression: an exploratory analysis of a single-blind randomized trial.
Topics: Adolescent; Antidepressive Agents; Bupropion; Chronic Disease; Citalopram; Cyclohexanols; Depressive | 2012 |
Escitalopram/reboxetine combination in depressed patients with substance use disorder.
Topics: Adult; Alcoholism; Antidepressive Agents; Bipolar Disorder; Citalopram; Depressive Disorder, Major; | 2005 |
Acceptability of second-step treatments to depressed outpatients: a STAR*D report.
Topics: Adult; Ambulatory Care; Citalopram; Clinical Protocols; Cognitive Behavioral Therapy; Combined Modal | 2007 |
Family history of completed suicide and characteristics of major depressive disorder: a STAR*D (sequenced treatment alternatives to relieve depression) study.
Topics: Adult; Age of Onset; Antidepressive Agents, Second-Generation; Bipolar Disorder; Citalopram; Cogniti | 2008 |
13 other studies available for citalopram and Chemical Dependence
| Article | Year |
|---|---|
Citalopram intoxication in four week old infant.
Topics: Child; Citalopram; Gastroesophageal Reflux; Humans; Infant; Seizures; Substance-Related Disorders | 2020 |
Serotonergic 5HTTLPR/rs25531 s-allele homozygosity associates with violent suicides in male citalopram users.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Case-Control S | 2017 |
Suspected Driving Under the Influence Case Involving Mitragynine.
Topics: Accidents, Traffic; Adult; Amphetamines; Citalopram; Driving Under the Influence; Female; Forensic T | 2018 |
Effects of chronic mild stress on the development of drug dependence in rats.
Topics: Animals; Chronic Disease; Citalopram; Depressive Disorder; Diazepam; Disease Models, Animal; Flumaze | 2014 |
Drug-induced long QT syndrome increases the risk of drowning.
Topics: Alcohol Drinking; Citalopram; Diving Reflex; Drowning; Humans; Long QT Syndrome; Methamphetamine; Mo | 2016 |
Concurrent anxiety and substance use disorders among outpatients with major depression: clinical features and effect on treatment outcome.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Anxiety; Citalopram; Depressive D | 2009 |
Family history of depression and therapeutic outcome: findings from STAR*D.
Topics: Adult; Age Factors; Alcoholism; Antidepressive Agents; Anxiety Disorders; Citalopram; Comorbidity; C | 2009 |
Major depressive disorder and medical illness: STAR*D outcomes.
Topics: Adult; Antidepressive Agents, Second-Generation; Chronic Disease; Citalopram; Comorbidity; Cross-Sec | 2006 |
Factors associated with concomitant psychotropic drug use in the treatment of major depression: a STAR*D Report.
Topics: Adolescent; Adult; Aged; Anti-Anxiety Agents; Antidepressive Agents, Second-Generation; Citalopram; | 2009 |
The pathogenetic role of adulterants in 5 cases of drug addicts with a fatal outcome.
Topics: Adult; Anesthetics, Local; Antitussive Agents; Bile; Brain Chemistry; Caffeine; Central Nervous Syst | 2013 |
Escitalopram-associated serotonin toxicity.
Topics: Adult; Antidepressive Agents, Second-Generation; Citalopram; Depression; Drug-Related Side Effects a | 2007 |
Caffeine consumption, sleep, and affect in the natural environments of depressed youth and healthy controls.
Topics: Adolescent; Affect; Anxiety Disorders; Attention Deficit Disorder with Hyperactivity; Beverages; Caf | 2008 |
Effects of "Ecstasy" blocked by serotonin reuptake inhibitors.
Topics: Adult; Citalopram; Female; Hallucinogens; Humans; N-Methyl-3,4-methylenedioxyamphetamine; Paroxetine | 1999 |